The faculty of two institutions, Weill Medical College and Sloan-Kettering Institute, are requesting funds to support a collaborative training program in basic research in the area of cancer pharmacology. The collaboration consists of an integrated set of training activities for Ph.D. students and postdoctoral fellows. The strength and diversity of the 15 faculty provide opportunities for research in a variety of different areas, such as the development of new cancer therapeutic agents (e.g. through organic synthesis, monoclonal antibody technology, differentiation therapy, and the screening of new compounds), and the analysis of molecular mechanisms by which some drugs cause apoptosis. Research on the control of side effects generated from current treatment modalities [eg. the use of growth factors such as G-CSF to reduce complications associated with bone marrow toxicity] is also a strength. Strategies for overcoming drug resistance are also being developed. Additionally, research concerning the mechanisms by which dioxin and environmental pollutants cause cancer is a part of the training program. The research includes basic mechanistic studies of the molecular actions of drugs used in cancer treatment and cancer prevention, and research leading to more clinical endpoints. The graduate Ph.D. program consists of course work and three lab rotations, followed by an admission to candidacy exam and thesis research. A graduate course in Cancer Pharmacology, initiated ten years ago, is part of this program and represents a commitment of the faculty to the training of students in this area. This training program sponsors a separate seminar series devoted to the area of cancer pharmacology and therapeutics to expose trainees to the research in this area, and students and fellows present their research at the annual two-day Pharmacology Program retreat. Fellows attend a weekly journal club, take courses in cancer pharmacology, and present a formal seminar in the cancer pharmacology seminar series. It is expected that this program will provide students and fellows with a broader understanding of the interrelationships between research on the basic mechanisms of drug action and drug development and clinical issues so that both clinicians and basic scientists will be better prepared to carry out research to prevent or treat cancer. Our request for continued NIH support of a training program in Cancer Pharmacology builds on major commitments of the participating institutions to the enhancement of research in this area. The faculty of this training program are members of the joint WMC/SKI graduate program, with a total of 28 Pharmacology Program faculty. Thus, this faculty represents a cohesive, interactive group of individuals who share a common interest in research and training in the area of cancer pharmacology. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA062948-13
Application #
7271830
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
1994-09-01
Project End
2010-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
13
Fiscal Year
2007
Total Cost
$499,596
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Guney, Tezcan; Wenderski, Todd A; Boudreau, Matthew W et al. (2018) Synthesis of Benzannulated Medium-ring Lactams via a Tandem Oxidative Dearomatization-Ring Expansion Reaction. Chemistry 24:13150-13157
Trasino, Steven E; Tang, Xiao-Han; Shevchuk, Maria M et al. (2018) Amelioration of Diabetic Nephropathy Using a Retinoic Acid Receptor ?2 Agonist. J Pharmacol Exp Ther 367:82-94
Patil, Deepak P; Pickering, Brian F; Jaffrey, Samie R (2018) Reading m6A in the Transcriptome: m6A-Binding Proteins. Trends Cell Biol 28:113-127
Quintero, Cynthia M; Laursen, Kristian B; Mongan, Nigel P et al. (2018) CARM1 (PRMT4) Acts as a Transcriptional Coactivator during Retinoic Acid-Induced Embryonic Stem Cell Differentiation. J Mol Biol 430:4168-4182
Galletti, Giuseppe; Worroll, Daniel; Nanus, David M et al. (2017) Using circulating tumor cells to advance precision medicine in prostate cancer. J Cancer Metastasis Treat 3:190-205
Sims, Christopher M; Hanna, Shannon K; Heller, Daniel A et al. (2017) Redox-active nanomaterials for nanomedicine applications. Nanoscale 9:15226-15251
Mathias, M D; Ortiz, M V; Magnan, H et al. (2017) A case report of concurrent embryonal rhabdomyosarcoma and diffuse large B-cell lymphoma in an adult without identifiable cancer predisposition. Biomark Res 5:7
Levinson, Adam M; McGee, John H; Roberts, Andrew G et al. (2017) Total Chemical Synthesis and Folding of All-l and All-d Variants of Oncogenic KRas(G12V). J Am Chem Soc 139:7632-7639
Jena, Prakrit V; Galassi, Thomas V; Roxbury, Daniel et al. (2017) Progress Towards Applications of Carbon Nanotube Photoluminescence. ECS J Solid State Sci Technol 6:M3075-M3077
Harvey, Jackson D; Jena, Prakrit V; Baker, Hanan A et al. (2017) A Carbon Nanotube Reporter of miRNA Hybridization Events In Vivo. Nat Biomed Eng 1:

Showing the most recent 10 out of 148 publications